Broadly Neutralizing Antibodies

Preferred Label : Broadly Neutralizing Antibodies;

MeSH definition : Neutralizing antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent (e.g., HIV) by targeting several epitopes.;

MeSH synonym : Antibodies, Broadly Neutralizing; Neutralizing Antibodies, Broadly; Broad Neutralizing Antibody; Antibody, Broad Neutralizing; Neutralizing Antibody, Broad; Cross-Neutralizing Antibodies; Antibodies, Cross-Neutralizing; Cross Neutralizing Antibodies; bnAb; Broad Neutralizing Antibodies; Antibodies, Broad Neutralizing; Neutralizing Antibodies, Broad; bnAbs; Cross-Neutralizing Antibody; Antibody, Cross-Neutralizing; Cross Neutralizing Antibody; Broadly Neutralizing Antibody; Antibody, Broadly Neutralizing; Neutralizing Antibody, Broadly; Broad Spectrum Antibodies; Antibodies, Broad Spectrum; Spectrum Antibodies, Broad;

Details

Origin ID

D000080908;

UMLS CUI

C5197773;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- drug effects [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- physiology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- ultrastructure [MeSH Qualifier]
- urine [MeSH Qualifier]
Record concept(s)
- Broadly Neutralizing Antibodies [MeSH concept]
Related MeSH Supplementary Concept(s)
- 2F5 monoclonal antibody [MeSH Supplementary Concept]
- 2G12 monoclonal antibody [MeSH Supplementary Concept]
- 3BNC117 antibody [MeSH Supplementary Concept]
- 4Dm2m [MeSH Supplementary Concept]
- 4E10 monoclonal antibody [MeSH Supplementary Concept]
- 64Cu-DOTA-patritumab [MeSH Supplementary Concept]
- AR4A cross-neutralizing monoclonal antibody [MeSH Supplementary Concept]
- AVP-21D9 [MeSH Supplementary Concept]
- BIIB023 [MeSH Supplementary Concept]
- CF172 antibody [MeSH Supplementary Concept]
- Fletikumab [MeSH Supplementary Concept]
- PB-2452 [MeSH Supplementary Concept]
- VIS410 monoclonal antibody [MeSH Supplementary Concept]
- VRC01 monoclonal antibody [MeSH Supplementary Concept]
- actoxumab [MeSH Supplementary Concept]
- bezlotoxumab [MeSH Supplementary Concept]
- carlumab [MeSH Supplementary Concept]
- dusigitumab [MeSH Supplementary Concept]
- patritumab [MeSH Supplementary Concept]
- suvratoxumab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients